Morningstar - IQVIA Holdings Inc (IQV) IQVIAs Life Sciences Cloud Business Continues to Soar; Raising FVE to $131 Following Investor Day

Report

Morningstar

Anna Baran

EUR 100.00 For Business Accounts Only

IQVIA's Life Sciences Cloud Business Continues to Soar; Raising FVE to $131 Following Investor Day

We are raising our fair value estimate for IQVIA to $131 per share following its investor day on June 18, where management laid out its strategy for growth through 2022 as well as plans for additional cost savings and deleveraging. The company continues to fire on all cylinders, with strong growth in both of its key segments, technology and analytics and research and development. We continue to believe shares look rich, but we believe that the narrow-moat company is competitively well positioned...

19/06/2019 14 EN

Underlying

IQVIA Holdings Inc

IQVIA Holdings is a provider of analytics, technology solutions and contract research services to the life sciences industry. The company's reportable segments are: Technology and Analytics Solutions, which provides information, technology solutions and real world solutions and services to life science clients; Research and Development Solutions, which primarily serves biopharmaceutical clients, is engaged in research and development and provides clinical research and clinical trial services; and Contract Sales and Medical Solutions, which provides contract sales to both biopharmaceutical clients and the healthcare market.

See profile

US46266C1053 New York Stock Exchange United States

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Anna Baran

Other Reports on these Companies

SmartInsider

IQVIA Holdings Inc: 2 directors

Two Directors at IQVIA Holdings Inc sold/sold after exercising options 45,778 shares at between 247.804USD and 250.527USD. The significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activi...

Free Trial

March 5, 2024 March 5, 2024 1 EN

Moody's Investors Service

Moody's assigns Baa3 rating to IQVIA's new senior secured notes, Ba2 rating to new senior unsecured notes

Moody's Investors Service (Moody's) assigned Baa3 rating to the proposed US dollar-denominated senior secured notes, and Ba2 rating to the proposed senior unsecured notes of IQVIA Inc. ("IQVIA"). There are no changes to IQVIA's existing ratings, including the Ba1 corporate family rating (CFR), Ba1-P...

EUR 165.82

May 18, 2023 May 18, 2023 1 EN

TheScreener

IQVIA HOLDINGS sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of IQVIA HOLDINGS (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date January 18, 2022, the closing price was USD 242.32 and its target price was estimated at USD 230.20.

Free Trial

January 19, 2022 January 19, 2022 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Joe Gemino

Joe Gemino

Sasol Provides Full-Year Production Update

No-moat Sasol provided an update on its full-year fiscal 2019 production metrics that included relatively stable liquids production. For the full year ended June 30, Sasol produced 1,470 thousand barrels of crude oil and condensate a day compared with 1,469 mboe/d in the year-ago period. However, declines continued with the companyâ€™s natural gas production, down 4% to 130.3 billion cubic feet compared with the period ended June 30, 2018. Sasol also reported flat refined products of 31.4 mmboe/d ...

EUR 100.00

July 25, 2019 July 25, 2019 12 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

IQVIA's Life Sciences Cloud Business Continues to Soar; Raising FVE to $131 Following Investor Day

IQVIA Holdings Inc: 2 directors

Moody's assigns Baa3 rating to IQVIA's new senior secured notes, Ba2 rating to new senior unsecured notes

IQVIA HOLDINGS sees a downgrade to Slightly Negative on account of less fundamental stars

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Sasol Provides Full-Year Production Update

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe